FDA Oncology Announcements

IL-3 fused immunotoxin × Myeloid × Clear all

1 Announcement

FDA approves tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm

Drug: ELZONRIS (tagraxofusp-erzs) · IL-3 fused immunotoxin
Condition: Myeloid